New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes
August 26, 2022 08:19 ET
|
Amarin Corporation plc
-- Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses -- -- Data Presented During Late-Breaking Science Session at...
Latest Research Evaluating VASCEPA®/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT® Landmark Outcomes Trial to be Presented at the European Society of Cardiology (ESC) Congress
August 15, 2022 08:00 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research on the effects of VASCEPA®/VAZKEPA...
Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update
August 03, 2022 07:00 ET
|
Amarin Corporation plc
Company Received Final Positive Reimbursement Decision for VAZKEPA® by UK’s NICE in England & Wales Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple...
Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022
July 20, 2022 08:00 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior...
NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & Wales
July 13, 2022 08:00 ET
|
Amarin Corporation plc
-- Newly published final guidance by the National Institute for Health and Care Excellence (NICE) in the UK confirms its prior draft recommendation for the use of VAZKEPA® (icosapent ethyl) in England...
REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo
June 30, 2022 16:05 ET
|
Amarin Corporation plc
-- Sub-Analysis Findings Support Prior Analyses that Eicosapentaenoic Acid (EPA) Level is The Major Determinant of Benefit in REDUCE-IT -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2022 ...
Amarin Receives Positive Recommendation from United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA® (icosapent ethyl)
June 10, 2022 06:00 ET
|
Amarin Corporation plc
UK’s NICE issued its draft Final Appraisal Document (FAD) recommending the use of VAZKEPA® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult...
Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business
June 06, 2022 08:30 ET
|
Amarin Corporation plc
-- Company Expects to Achieve Approximately $100 Million in Cost Savings Over the Next 12 Months* While Continuing to Invest in European Launches and Global Expansion -- -- Reduces U.S. Commercial...
Amarin Appoints Tom Reilly as New Chief Financial Officer
June 06, 2022 08:15 ET
|
Amarin Corporation plc
-- Experienced Executive Brings More Than Twenty Years of Global Financial Leadership to Amarin -- -- Michael W. Kalb to Depart Amarin to Pursue Other Interests -- DUBLIN, Ireland and BRIDGEWATER,...
Amarin Announces Appointment of New Directors and Board Leadership Changes
May 19, 2022 08:23 ET
|
Amarin Corporation plc
Erin Enright and Alfonso “Chito” Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company’s Strategy Per Wold-Olsen Named Chairman of the...